Clinical Trials Logo
  1. Home
  2. Chemotherapy
  3. NCT05261646

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Stage Phase Ⅲ Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets in Treatment of Chemotherapy-Induced Thrombocytopenia

Clinical Trial Summary

The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of chemotherapy regimen (i.e., delayed start, dose reduction, omission, or discontinuation) because of thrombocytopenia [platelet count <100×109/L], to determine an optimal dose of hetrombopag and to demonstrate its superiority over placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05261646
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Withdrawn
Phase Phase 3
Start date April 15, 2022
Completion date December 15, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969158 - Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma Phase 2
Active, not recruiting NCT03362177 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer Phase 3
Recruiting NCT05554913 - Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Completed NCT05688306 - To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
Completed NCT00283439 - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06099925 - The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies Phase 2
Completed NCT03471078 - Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers Phase 3
Active, not recruiting NCT03976882 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. Phase 3
Recruiting NCT05772546 - Avatrombopag vs. Placebo for CIT in GI Malignancies Phase 2
Not yet recruiting NCT05864014 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. Phase 3
Terminated NCT01345214 - A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia Phase 1
Completed NCT01663441 - A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 Phase 3
Recruiting NCT05236582 - Herombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Not yet recruiting NCT05944211 - Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia Phase 2
Withdrawn NCT03343847 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. Phase 3
Completed NCT05851027 - Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia Phase 2/Phase 3
Not yet recruiting NCT03049774 - A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor N/A
Recruiting NCT03937154 - Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Phase 3
Recruiting NCT05218226 - Avatrombopag for Chemotherapy-induced Thrombocytopenia Phase 2
Recruiting NCT04600960 - Eltrombopag for Chemotherapy-induced Thrombocytopenia Phase 2